TD Cowen maintains Caris Life Sciences at Buy, raises price target to $38 from $36
TD Cowen kept its Buy rating on Caris Life Sciences and increased its price target to $38 from $36, suggesting a 14.4% upside from the Nov 4 close of $33.22. Recent analyst price targets for the company range from $30 to $38.
How this was made

The 30-second read
Why it matters
Analyst price‑target lift signals confidence in upcoming data, but market reaction may be modest.
Market read
The new target may attract short‑term buying, but overall impact is limited.
What to watch
Potential regulatory or trial setbacks not reflected in the new target.
Background
Caris Life Sciences is a clinical‑stage biotech focused on cancer diagnostics.
Market effects
May boost sentiment in the biotech/life‑sciences sector as peers are re‑rated.
Limited to US markets where CRIS trades.
Minimal global impact beyond niche investors.
Counterpoint
The target raise could be premature if upcoming trial data disappoints.
Key entities
- analystTD Cowen
Equity research firm that issued the rating and target.

